Bausch & Lomb BLCO announced an agreement with Novartis to acquire dry eye drug Xiidra (along with a few early-stage eye care products) for $1.75 billion in upfront cash and potential sales-based ...

Please provide your email address to receive an email when new articles are posted on . Two-thirds of respondents said patients had near or complete symptom resolution after Xiidra treatment. Mild or ...

This summer, Bausch + Lomb unveiled plans to acquire a dry eye disease treatment from Novartis for up to $2.5 billion. Now, the eye health company has closed the deal. The purchase of XIIDRA, a 5% a ...

Bausch + Lomb is expanding its ophthalmology portfolio and pipeline, paying Novartis $1.75 billion to acquire a commercialized drug for dry eye disease along with two experimental eye products. The ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered ...

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has acquired Xiidra, and other dry eye disease assets, from Novartis. Xiidra may achieve better ...

Reproxalap Statistically Lower than Xiidra for the Two Endpoints of the Trial: Ocular Discomfort (p=0.002) and Ocular Itching (p=0.01) Results Consistent with Data from Post-Acute Ocular Tolerability ...

ZURICH (Reuters) - Swiss drugmaker Novartis has withdrawn an application for European approval of its Xiidra dry eye medicine after regulators concluded its effectiveness had not been demonstrated and ...

Novartis announced Friday that it will divest its ‘front of eye’ ophthalmology assets to global eye health company Bausch + Lomb for $2.5 billion. The sale includes Xiidra, an approved treatment for ...

This advertising content was written by the Bausch + Lomb team, and does not reflect the opinions or point of view of Vox Media or Vox Creative. Do you find yourself frequently reaching for ...